S. 4327 (119th)Passage Likelihood
A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.
domestic policy
Sponsor
Cosponsors
Support
Republican
Introduced
Apr 16, 2026
Discussions
Current stageCommittee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced
Committee
Floor
President
Law
Loading passage likelihood analysis...